HR Execs on the Move

Translational Genomics Research Institute

www.tgen.org

 
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization focused on developing earlier diagnostics and smarter treatments. Translational genomics research is a relatively new field employing innovative advances arising from the Human Genome Project and applying them to the development of diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.tgen.org
  • 445 North Fifth Street
    Phoenix, AZ USA 85004
  • Phone: 602.343.8400

Executives

Name Title Contact Details
Page Bachman
SVP of HR and Chief People Officer Profile
Robert Kennedy
VP of Finance Profile

Similar Companies

Solstice Neurosciences

Solstice Neurosciences is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

StemExpress

Leading Biospecimen Provider of human bone marrow, cord blood, peripheral blood, Leukopaks, Mobilized Leukopaks, and more. Click to visit our website!

Cidara

Cidara is developing therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company`s portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara`s proprietary Cloudbreak antiviral platform. Cidara is headquartered in San Diego, California.

OWKIN

OWKIN builds mathematical models and algorithms that can interpret omics, visual data, biostatistics and patient profiles like never before. With OWKIN, patients directly benefit with more effective treatments.

Rosetta Genomics

Founded in 2000, Rosetta's integrative research platform combining bioinformatics and state-of- the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.   Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools and therapeutics.   Rosetta currently commercializes a full range of microRNA-based molecular diagnostics. Rosetta's cancer testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.